Human tumors consist of heterogeneous populations with different phenotypic characteristics, and these subpopulations can often be distinguished by different surface marker expression. In head and neck squamous cell carcinoma (HNSCC), CD44 has been identified to be a marker of a subpopulation, containing the tumor-initiating cells (or cancer stem cells), which are capable of self-renewal and differentiation into cells lacking this capacity. Significant evidence indicates that these tumorinitiating cells have an immune suppressive phenotype, allowing them to evade the antitumor host immune response, leading some to hypothesize that these cells may contribute to long-term tumor dormancy. In this study, we profiled 21 primary human HNSCC tumors and/or patient-derived xenografts for CD44 expression and PD-L1 ( 
